Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMX | P51813 | 11/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 6/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 3/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3136039 | 0.88 | BMX (0.57) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL3139703 | 0.85 | BMX (0.59) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL19922951 | 0.84 | TNK2 (0.67) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL13521817 | 0.84 | BMX (0.65) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL3134937 | 0.83 | TNK2 (0.69) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL13521818 | 0.82 | TNK2 (0.77) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL3135665 | 0.78 | TNK2 (0.84) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL19922636 | 0.77 | TNK2 (0.42) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL3827669 | 0.77 | TNK2 (0.66) | BMXTNK2MAP4K2ABL1BCR | |
| SCHEMBL3139709 | 0.76 | TNK2 (0.73) | BMXTNK2MAP4K2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | BMX 1/4885TNK2 203/4885MAP4K2 37/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | BMX 1/4885TNK2 203/4885MAP4K2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.